TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity

BACKGROUND: Patients with diabesity have a significantly increased risk of developing cardiovascular disease. Therefore, therapy addressing the multiple metabolic abnormalities linked with diabesity and leading to further reduction of cardiovascular risk is highly desirable. Activation of the TGR5 r...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Zambad, Shitalkumar P, Tuli, Davinder, Mathur, Anoop, Ghalsasi, Sameer A, Chaudhary, Anita R, Deshpande, Shailesh, Gupta, Ramesh C, Chauthaiwale, Vijay, Dutt, Chaitanya
פורמט: Artigo
שפה:Inglês
יצא לאור: Dove Medical Press 2013
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3873233/
https://ncbi.nlm.nih.gov/pubmed/24379686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S50209
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים